Biologicals Robigo and Leaps by Bayer Secure Series A Funding
Robigo, a biotechnology company developing engineered biological solutions for crop protection, has announced a new Series A financing round led by Leaps by Bayer. The funding round also includes participation from Illumina Ventures, SVG Thrive, Congruent Ventures, and Endeavor8.
The investment will help Robigo accelerate the commercial development and launch of its engineered microbial biopesticides designed to combat fungal diseases affecting soybeans and specialty crops in the United States. The company aims to demonstrate that biological crop protection products can deliver strong performance while remaining economically practical for growers.
In addition to supporting near-term commercialization, the Series A financing will enable Robigo to expand its development pipeline toward additional soil-borne pathogens affecting broadacre crops. According to the company, these opportunities represent an addressable market estimated at approximately $10 billion.
Developing a New Generation of Biological Crop Protection
Biologicals are increasingly becoming an important part of modern agriculture as farmers and crop protection companies seek additional tools for managing pests and diseases. While conventional chemical products remain an important component of crop protection, biological technologies can provide alternative modes of action and potentially complement existing solutions.
Crop diseases continue to create significant economic challenges for farmers worldwide. In the United States, soybean growers face substantial losses from Sudden Death Syndrome (SDS), a fungal disease that can reduce yields and create significant production costs. Robigo estimates that SDS results in approximately $200 million to $500 million in annual losses for U.S. soybean farmers.
The challenge extends beyond broadacre crops. Fusarium wilt has emerged as a major disease concern for growers of lettuce and berries. Limited and costly control options can make disease management particularly difficult, creating demand for new technologies that can be integrated into existing crop protection programs.
Robigo is developing its biological solutions with the goal of addressing these challenges through engineered microorganisms capable of delivering targeted biological activity.
Synthetic Biology at the Core of Robigo’s Technology
Robigo’s technology is based on synthetic biology, an approach that enables scientists to modify the genetic characteristics of living organisms for specific purposes. The company applies this approach to beneficial microbes, engineering them to produce traits and biological compounds intended to control agricultural pests and diseases.
At the center of the company’s technology portfolio is its ARGO™ platform. The platform combines computational design and microbial engineering to develop active ingredients intended to interfere with essential genes in disease-causing pathogens.
This gene-targeting approach is designed to create new modes of action for crop protection. Rather than relying exclusively on conventional approaches, Robigo seeks to develop biological products capable of precisely targeting pathogens while leveraging living microbial systems to deliver the desired activity.
The company says the ARGO™ platform is designed for rapid development and programmability. Robigo’s process brings together computational design, microbial engineering, laboratory validation, and field testing in an integrated development system.
According to the company, this approach can reduce the time required to progress a crop protection program from initial computational design through engineering, lead validation, and field testing to less than 20 months. That compares with a conventional industry development timeline that can take approximately three to five years.
Engineered Microbes Designed for Continuous Protection
One of the key features of Robigo’s approach is how its engineered microorganisms are intended to operate after application.
Rather than requiring repeated delivery of an active ingredient throughout the growing season, Robigo’s engineered microbes are designed to be applied as a one-time treatment. Following application, the microorganisms continuously produce and deliver ARGO™-designed active ingredients in areas where protection is needed.
The company believes this delivery system could provide season-long disease protection while requiring little or no change to existing grower practices.
This concept could be particularly relevant for diseases that develop within or around the plant’s root zone and soil environment. By positioning the biological system where disease pressure occurs, Robigo aims to create targeted protection while potentially improving the efficiency of active ingredient delivery.
The company is also focused on ensuring that its biological products can meet the practical requirements of commercial agriculture. For growers, performance is only one part of the equation. Products must also provide economic value and fit into established farming systems.
Making Biologicals More Economically Viable
The agricultural biologicals sector has attracted significant interest as companies work to develop alternatives and complements to traditional crop protection technologies. However, commercial adoption depends on more than biological innovation alone.
Robigo’s strategy focuses on combining biological performance with economics. The company says its objective is to develop products that can compete with existing crop protection technologies without requiring growers to compromise on effectiveness, affordability, or sustainability.
“At Robigo, we believe in building on nature’s foundation to engineer biological products that match or exceed the performance of today’s chemistries. Growers shouldn’t have to choose between a product that works and one that’s affordable or sustainable,” said Dr. Andee Wallace, Founder and CEO of Robigo.
The company’s approach therefore centers on using engineering and computational design to create biological products with specific and measurable functions.
Expanding the Crop Protection Pipeline
The Series A financing will also support the expansion of Robigo’s technology pipeline beyond its initial disease targets.
The company plans to use its ARGO™ platform to investigate additional soil-borne pathogens affecting broadacre crops. This could allow Robigo to apply the same underlying technology to a wider range of agricultural disease challenges rather than developing each product through an entirely separate discovery process.
This platform-based strategy is an important element of the company’s business model. Instead of relying on a single biological product, Robigo is developing an engineering system intended to generate multiple crop protection solutions.
Dr. Juergen Eckhardt, Executive Vice President and Head of Leaps by Bayer, highlighted this aspect of the company’s technology.
“The scalability of the ARGO™ platform is what sets Robigo apart,” Eckhardt said. “They are not just developing a single product but rather building an engine that can rapidly address diverse soil-borne pathogens across broadacre crops.”
He added that Robigo’s crop protection programs focus on significant agricultural diseases and could complement Bayer’s existing crop protection portfolio.
Supporting More Resilient Agriculture
The new investment comes as farmers and agricultural technology companies continue to explore ways to manage increasing disease pressure while improving the efficiency of crop production.
For growers, the availability of additional disease-management tools can provide greater flexibility when designing crop protection programs. Biological solutions may also provide opportunities to introduce different modes of action into disease management strategies, potentially complementing conventional chemistry and other technologies.
Robigo’s engineered microbial approach represents one example of how advances in biotechnology and computational design are being applied to agricultural challenges. By combining synthetic biology with a platform-based development model, the company aims to shorten development timelines and bring new biological crop protection products to farmers more efficiently.
The Series A financing gives Robigo resources to advance its near-term programs while expanding research into additional pathogens and crops. As the company progresses toward commercialization, its focus will remain on developing biological products that address significant disease challenges while meeting the performance and economic requirements of modern agriculture.
With its ARGO™ platform, Robigo is seeking to establish a scalable foundation for the development of engineered microbial crop protection products. The company’s strategy is to use biological engineering not simply as an alternative to conventional chemistry, but as a technology platform capable of generating targeted solutions for some of agriculture’s most persistent disease problems.
Source Link:https://www.businesswire.com/
